FDA Safety Pilot Prompts SNRI Relabeling; “Too Soon To Tell” Patient Impact
Executive Summary
FDA's pilot program to conduct post-market safety reviews of new molecular entities has catalyzed labeling changes for Lilly's Cymbalta, but its impact on patient safety remains uncertain